Blockchain Registration Transaction Record

NanoViricides' NV-387 Shows Breakthrough Anti-Measles Activity

NanoViricides announces NV-387 shows 130% survival extension in Measles models. Broad-spectrum antiviral advances to Phase II trials for MPox with no adverse events in Phase I human studies.

This development represents a potential breakthrough in treating Measles, a highly contagious disease that has seen resurgences globally despite vaccination efforts. With no currently approved treatments available, NV-387's demonstrated effectiveness in protecting lung tissue and extending survival by 130% in severe infection models could address a critical unmet medical need. The broad-spectrum nature of this antiviral candidate suggests it might also be effective against other respiratory viruses, potentially offering a versatile therapeutic option for future outbreaks. For public health systems, this could mean new tools to combat Measles outbreaks that still cause approximately 140,000 deaths annually worldwide, particularly in regions with limited vaccination coverage. The advancement also signals progress in nanomedicine approaches to viral infections, potentially opening new treatment paradigms beyond traditional antiviral medications.